Bionovo (BNVI)
Bionovo Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BNVI Revenue Growth Range, Past 5 Years
| Minimum | -90.40% | Dec 2011 |
| Maximum | 8849% | Dec 2007 |
| Average | 1725% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BNVI related companies
BNVI News
$BNVI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Czk
about 54 days ago by MarketBrief
about 54 days ago by MarketBrief
Technicals showing bullish accumulation. $BNVI now testing near term resistance levels off lows http://chart.ly/sswp6i3
about 122 days ago by Hereditarded
about 122 days ago by Hereditarded
Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
Oct 26, 4:38PM Benzinga
Oct 26, 4:38PM Benzinga
Bionovo gets additional 180 days to regain compliance with Nasdaq's bid rule
Sep 19, 8:08AM FlyOnTheWall
Sep 19, 8:08AM FlyOnTheWall
Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaq's Bid Price Rule
Sep 19, 8:06AM Benzinga
Sep 19, 8:06AM Benzinga
Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes
Aug 30, 8:00AM PR Newswire
Aug 30, 8:00AM PR Newswire
Bionovo to Host a Conference Call to Discuss Menerba's Tolerability Trial Results
Aug 29, 8:00AM PR Newswire
Aug 29, 8:00AM PR Newswire
@23aloha $bnvi i would call it firesale on very low volume. We might get a quick pop up again
about 306 days ago by onemillion2012
about 306 days ago by onemillion2012
@TroKalayjian will $bnvi be a winner in Q3..? What´s your take. It have been steady moving up from all time low
about 309 days ago by onemillion2012
about 309 days ago by onemillion2012
@benkingonbio @extremebiotech $bnvi It will move fast up. Like you say warrent at 1,30. And it will fly from there
about 310 days ago by onemillion2012
about 310 days ago by onemillion2012
@TroKalayjian You also deserve credit for bringing $BNVI to our attention. Has been nice mover since. Thanks for the good work.
about 311 days ago by BioDude
about 311 days ago by BioDude
$BNVI gettin its wheels turning again, $INO seeing a little insider buying, $DRRX great buy at this price,also, $FTWR due for another bounce
about 333 days ago by JoeyCoberly
about 333 days ago by JoeyCoberly
$BNVI Stay out pump and short scam ongoing! 58% short volume on June 10th!
about 351 days ago by mid_swe
about 351 days ago by mid_swe
$bnvi Get in now... We have tested 0,80 area 3 day´s in last week. It´s a matter of time before we test the 0,90
about 353 days ago by onemillion2012
about 353 days ago by onemillion2012
$bnvi sorry forthe bad info this info was for another stock with sim. name that i own
about 359 days ago by cattosa
about 359 days ago by cattosa
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BNVI | 0.116 | +0.00 | +0.00% | |
| BNS | 49.49 | -0.58 | -1.16% | 53.92B |
| BNHN | 16.13 | +0.00 | +0.00% | 288.40M |
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMR | 18.25 | -0.17 | -0.92% | 2.815B |
| BMO | 52.99 | -0.73 | -1.36% | 33.94B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BLC | 5.85 | -0.03 | -0.51% | 608.52M |
| BKYF | 23.80 | -0.23 | -0.96% | 177.31M |
| BKT | 7.52 | +0.00 | +0.00% |
